quantisnow
FeedTopReportsPricing
⌘K
Live feed
10:32:00·2d
PRRelease
Karyopharm Therapeutics Inc. logo

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting

KPTI· Karyopharm Therapeutics Inc.
Health Care
Original source

Companies

  • KPTI
    Karyopharm Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 10UpdateRodman & Renshaw$28.00
  • Feb 5UpdateCantor Fitzgerald-
  • Oct 13UpdateH.C. Wainwright$15.00
  • Jul 16UpdateH.C. Wainwright-
  • Jul 11UpdateH.C. Wainwright$27.00
  • Jan 19UpdatePiper Sandler$8.00

Related

  • INSIDER1d
    SEC Form 4 filed by Rangwala Reshma
  • SEC10d
    Amendment: SEC Form SCHEDULE 13G/A filed by Karyopharm Therapeutics Inc.
  • SEC11d
    SEC Form DEF 14A filed by Karyopharm Therapeutics Inc.
  • SEC21d
    SEC Form SCHEDULE 13G filed by Karyopharm Therapeutics Inc.
  • SEC21d
    SEC Form SCHEDULE 13G filed by Karyopharm Therapeutics Inc.
  • SEC28d
    SEC Form 8-K filed by Karyopharm Therapeutics Inc.
  • SEC31d
    Karyopharm Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure
  • PR31d
    Karyopharm Announces $30 Million Private Placement with RA Capital
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022